Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Fidelity Growth Strategies Fund Shilpa Mehra | “Not holding IDEXX Labs (+6%), a maker of veterinary products and a sizable benchmark component, also hurt. IDEXX is a solid and consistent business, and in its latest quarterly update, reported in November, it delivered strong results that materially outperformed expectations. But we don't think the current growth is sustainable over the longer term and prefer other investments in the mid-cap growth universe. BSD Analysis: IDEXX Laboratories enters 2026 with strong momentum, recently reporting fourth-quarter 2025 earnings of $3.08 per share which comfortably beat Wall Street consensus. The company is successfully leveraging its CAG Diagnosticssegment to drive 10% organic recurring revenue growth, outperforming broader animal health sector levels. For 2026, management has issued an optimistic sales forecast of up to $4.72 billion, led by a record instrument placement cycle including the new inVue Dx platform. While the stock saw a technical dip following its earnings release, the firm's gross margins have expanded to 60.3% due to effective net price realization and reference laboratory productivity. Management is focusing on the "aging pet population" trend, which is driving higher diagnostic frequency and long-term brand loyalty among veterinarians. For investors, IDEXX remains a high-quality, recession-resistant play on the structural humanization of pets globally.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Baron Partners Fund Ron Baron | “Veterinary diagnostics leader IDEXX Laboratories, Inc. spent years developing new tests. One was released in 2025, and another is expected to come to market in 2026. Utilization of new tests has exceeded expectations. The company contributed to performance after again reporting better-than-expected financial results. We believe IDEXX's competitive trends are outstanding, and we expect new proprietary innovations, such as InVue, MultiCue, and CancerDX to be meaningful contributors to growth in the years ahead. We also see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate. The stock appreciated 63.6% in 2025. BSD Analysis: IDEXX issued a bullish initial outlook for 2026, projecting revenue between $4.63 billion and $4.72 billion (up 7%–9% organic). The growth is led by CAG Diagnostics recurring revenue, which is expected to rise 8%–10% organically, fueled by diagnostic innovation and a 4% net price improvement. However, management anticipates a decline in instrument revenue as it laps the record placement cycle of the IDEXX InVue Dx. 2026 EPS guidance is set at $14.29–$14.80, reflecting a targeted 40–90 basis point operating margin expansion. Despite pressure on clinical visits (projected -2% for 2026), IDEXX remains a "Moderate Buy" due to its aggressive share repurchases and dominant 24.6% net margin.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Conestoga Mid Cap Composite Conestoga Capital Advisors, LLC | “IDEXX Laboratories, Inc. (IDXX) was a major contributor during the quarter as it continued to deliver resilient organic revenue growth despite weaker veterinary visit trends. The company posted robust quarterly results, reinforcing its leadership position in veterinary diagnostics. Consumables adoption and instrument placement supported recurring revenue growth. Shares re-rated toward historical valuation averages as confidence in earnings durability improved. We believe IDEXX remains a high-quality defensive growth asset within health care. BSD Analysis: IDEXX is the quiet monopoly in companion animal diagnostics, and the market still underestimates how locked-in its customers really are. Vet clinics don't rip out diagnostic workflows once they're embedded, which makes recurring revenue incredibly durable. Growth slows when pet adoption normalizes, but testing intensity per visit keeps rising. Pricing power exists because outcomes matter more than cost in animal health. The installed base acts like an annuity with incremental software and consumables layered on top. Investors worry about valuation every cycle and then watch it hold anyway. Margins reflect IP and switching costs, not volume chasing. IDEXX doesn't need growth heroics to work. This is healthcare infrastructure for pets, priced like a growth stock for a reason.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Platinum International Brands Fund Nik Dvornak | “IDEXX benefits from secular growth in companion animal healthcare and increasing diagnostic penetration. Its installed base creates recurring consumables revenue with high margins. Innovation and switching costs support pricing power. We view IDEXX as a high-quality compounder with long-term earnings visibility. BSD Analysis: IDEXX is the undisputed leader in veterinary diagnostics, riding the secular rise of pet healthcare spending. Its razor/razor-blade model — instruments plus consumables — creates exceptionally sticky, high-margin recurring revenue. Vet clinics depend on IDEXX workflows, making churn nearly nonexistent. As pets become “family members,” diagnostic intensity keeps rising. The company innovates relentlessly, maintaining technological leadership. IDEXX is one of the highest-quality healthcare tools businesses in the world. A true elite compounder.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Conestoga Mid Cap Composite Conestoga Capital Advisors, LLC | “IDEXX Laboratories, Inc. (IDXX) IDXX is the industry leader in providing instruments (and consumables) used in diagnostics, detection, and information systems for veterinary, food, and water testing applications. Earnings for the quarter were solid and guidance for high-single-digit organic revenue growth was maintained, despite weak traffic trends. Shares rallied off five-year low valuation and the 'better-than-feared' results in the quarter. BSD Analysis: IDEXX is a high-quality, recurring-revenue diagnostic franchise levered to structurally rising pet health spending and global testing needs. Its razor-razorblade model in vet clinics drives sticky, high-margin consumables and software revenue. Maintaining high-single-digit organic growth despite softer traffic highlights the resilience of demand and pricing power. The stock had de-rated to a multi-year low valuation, creating an opportunity as fundamentals remain intact and margins have room to expand with scale. Over the medium term, increasing penetration of diagnostic testing and software integration should support above-market earnings growth and renewed multiple expansion.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
